Amit Singal, MD

home / authors / amit-singal-md

Articles

Case 4: Later Lines of Therapy for Patients With Recurrent HCC

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 29th 2022

Expert panelists consider later-line treatment options for a patient with recurrent hepatocellular carcinoma.

Case 3: Novel Frontline Combination Strategies for Unresectable HCC

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 29th 2022

Comprehensive insight on several clinical trials analyzing frontline combination therapies for patients with unresectable hepatocellular carcinoma.

Case 3: A 63-Year-Old With Unresectable HCC Eligible for IO Therapy

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 29th 2022

In the setting of unresectable hepatocellular carcinoma, experts consider the role of frontline atezolizumab + bevacizumab given data from IMbrave150.

Case 2: Treating Child-Pugh B Metastatic Hepatocellular Carcinoma

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 22nd 2022

A brief review of treatment options for patients with Child-Pugh B grade metastatic hepatocellular carcinoma.

Case 2: Adverse Event Management and Dosing of Frontline TKIs

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 22nd 2022

Panelists consider the adverse event profile of frontline TKI therapy in patients with metastatic HCC and review options for dosing and dose reduction.

Case 2: PFS Subgroup Data From the REFLECT Trial in Metastatic HCC

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 15th 2022

Comprehensive discussion on the PFS subgroup data from REFLECT, which compared frontline lenvatinib and sorafenib therapy in metastatic HCC.

Case 2: Data Supporting Frontline TKI Therapy in Metastatic HCC

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 15th 2022

Shared insight on clinical trial data in metastatic hepatocellular carcinoma supporting frontline use of sorafenib and lenvatinib, respectively.

Case 2: Selecting Frontline Therapy for Metastatic HCC

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 8th 2022

Focused discussion on the frontline treatment options available for patients diagnosed with metastatic hepatocellular carcinoma.

Case 2: Role of Biopsy and Imaging in Metastatic HCC

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 8th 2022

Panelists debate the role of imaging in conjunction with or in place of biopsy in the setting of metastatic hepatocellular carcinoma.

Case 2: A 75-Year-Old With Metastatic HCC

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 1st 2022

Shifting to a second patient case of metastatic hepatocellular carcinoma, experts consider best diagnostic practices and the initiation of therapy.

Case 1: Systemic Therapy in Combination With or Following TACE/TARE

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 1st 2022

A brief discussion on the role of systemic therapies in combination with or following TACE/TARE in unresectable hepatocellular carcinoma.

Case 1: Role of TARE in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

June 24th 2022

Expert perspectives on the role of transarterial radioembolization in unresectable hepatocellular carcinoma following FDA approval.

Case 1: A 60-Year-Old With Unresectable Hepatocellular Carcinoma

Ghassan K. Abou-Alfa, MD;Amit Singal, MD;Mark Yarchoan, MD;Riad Salem, MD, MBA

June 24th 2022

Sharing the first patient case of unresectable hepatocellular carcinoma, experts consider optimal screening and diagnosis practices in this setting.

Investigators Are Exploring Neoadjuvant and Adjuvant Therapy in HCC

Amit Singal, MD

June 2nd 2021

Amit Singal, MD, discusses options after surgical resection for patients with hepatocellular carcinoma.

Curative and Palliative Treatment Options for Patients With Hepatocellular Carcinoma

Amit Singal, MD

September 22nd 2019

Amit Singal, MD, discusses the current treatment landscape for patients with hepatocellular carcinoma and how the treatments differ among patients caught in early-stage versus late-stage at the 2019 International Liver Cancer Association Annual Conference.